Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab versus oxaliplatin plus fluoropyrimidine in untreated advanced gastric or gastroesophageal junction cancer
2016-001018-76Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, oxaliplatin, capecitabine, folinic acid and 1 more in gastric cancer (GC) and esophagogastric junction cancer (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall survival in PD-L1-expressing tumors. Started Aug 2016; status: active.
02
Drugs
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2016-001018-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001018-76.